Literature DB >> 7586077

Synthesis and antitumor activity of duocarmycin derivatives.

S Nagamura1, Y Kanda, E Kobayashi, K Gomi, H Saito.   

Abstract

A series of duocarmycin B2 derivatives, modified at the phenolic hydroxyl group to ester, carbonate and carbamate, was synthesized. Antitumor activity of these analogs was preliminarily evaluated by assays of growth inhibition of HeLa S3 cells (in vitro) and antitumor activity against murine sarcoma 180 (in vivo). The stability of the compounds under aqueous conditions was examined, and we found a correlation between antitumor activity in vivo and stability in aqueous solution, that is, the more stable derivatives exhibited higher antitumor activity. Among these derivatives, the N,N-dialkylcarbamoyl analogs exhibited both improved antitumor activity and higher stability compared with duocarmycin B2. These analogs were subjected to further biological evaluation and they expressed broad-spectrum activity toward murine solid tumors M5076, Colon 26 and Colon 38, and human xenografted carcinoma MX-1.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7586077     DOI: 10.1248/cpb.43.1530

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  5 in total

1.  A five-membered lactone prodrug of CBI-based analogs of the duocarmycins.

Authors:  Mika Uematsu; Daniel M Brody; Dale L Boger
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

2.  Efficacious cyclic N-acyl O-amino phenol duocarmycin prodrugs.

Authors:  Amanda L Wolfe; Katharine K Duncan; Nikhil K Parelkar; Douglas Brown; George A Vielhauer; Dale L Boger
Journal:  J Med Chem       Date:  2013-05-10       Impact factor: 7.446

3.  A novel, unusually efficacious duocarmycin carbamate prodrug that releases no residual byproduct.

Authors:  Amanda L Wolfe; Katharine K Duncan; Nikhil K Parelkar; Scott J Weir; George A Vielhauer; Dale L Boger
Journal:  J Med Chem       Date:  2012-06-12       Impact factor: 7.446

4.  A unique class of duocarmycin and CC-1065 analogues subject to reductive activation.

Authors:  Wei Jin; John D Trzupek; Thomas J Rayl; Melinda A Broward; George A Vielhauer; Scott J Weir; Inkyu Hwang; Dale L Boger
Journal:  J Am Chem Soc       Date:  2007-11-17       Impact factor: 15.419

5.  A fundamental relationship between hydrophobic properties and biological activity for the duocarmycin class of DNA-alkylating antitumor drugs: hydrophobic-binding-driven bonding.

Authors:  Amanda L Wolfe; Katharine K Duncan; James P Lajiness; Kaicheng Zhu; Adam S Duerfeldt; Dale L Boger
Journal:  J Med Chem       Date:  2013-08-29       Impact factor: 7.446

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.